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Oxidative stress is closely involved in age-related diseases and ageing itself. There is evidence of the leading contribution of
oxidative damage to neurodegenerative disease, in contrast to other diseases where oxidative stress plays a secondary role. The
42-mer amyloid β (Aβ42) peptide is thought to be a culprit in the pathogenesis of Alzheimer’s disease (AD). Aβ42 aggregates form
the oligomeric assembly and show neurotoxicity, causing synaptic dysfunction. Aβ42 also induces tissue oxidation (DNA/RNA,
proteins,andlipids)throughtracemetals(Cu,Zn,andFe),whichcanbeprotectedbyantioxidantenzymes,vitaminC,andvitamin
E. Superoxide dismutase catalyzes the conversion of toxic superoxide radical to less reactive hydrogen peroxide, contributing to
protection from AD. Here we review the involvement of oxidative stress in AD progression induced from an imbalance between
the radical formation of Aβ42 itself together with unique turn structure at positions Glu22 and Asp23 and several defense systems.
1. OxidativeStressinAgeing—The Involvement
of SuperoxideRadical
Oxidative stress caused by reactive oxygen species (ROS)
has been implicated in numerous age-related diseases and
ageing itself [1, 2]. ROS include superoxide anions, hydrogen
peroxide, hydroxyl radicals, and singlet oxygen. ROS are also
involved in neurodegeneration such as Alzheimer’s disease
(AD), Parkinson’s disease, and amyotrophic lateral sclerosis,
because the brain is one of the most vulnerable tissues in the
body to oxidative injuries based on its high rate of oxygen
consumption [3]. The hydroxyl radical is believed to be
one of the main stimuli of oxidative damage (Figure 1)a n d
reacts with several biomolecules, leading to the formation of
8-hydroxydeoxyguanosine (8-OHdG)/8-hydroxyguanosine
(8-OHG) in DNA/RNA, the formation of methionine sul-
foxide, carbonylation in proteins, and lipid peroxidation. In
particular, lipid peroxidation can lead to the production of
4-hydroxyl nonenal (4-HNE), malondialdehyde (MDA), and
thiobarbituric acid-reacting substances (TBARS) as byprod-
ucts. The subsequent processes to hydroxyl radical could be
involved in peroxynitrite formation by stimulating inducible
nitric oxide synthase (i-NOS). Hydrogen peroxide (H2O2)i s
less reactive but is involved in the Fenton reaction (Haber-
Weiss procedure, Figure 1), providing the hydroxyl radical.
On the other hand, the superoxide radical is also
biologically toxic, especially under the condition of radical-
radical reactions which could occur at a diﬀusion-controlled
rate. It presents widely in high quantity. A small fraction
(0.4%–4%)ofoxygenutilizedinthemitochondriaisreduced
by single electron transfer during the initial step of the
electron transport chain, followed by the generation of
superoxide radical [4]. Catalase and peroxidases (such as
glutathione peroxidase: GPx), which exists in ubiquitous
tissues, can eliminate H2O2 generated from superoxide
radicals (Figure 1).
Superoxide dismutases (SODs) are the main antioxidant
enzymes that convert superoxide anions to H2O2, protecting
cells and tissues from ROS generated from endogenous
and exogenous sources [5]. SODs consist of three types of
isoforms expressed in mammalian cells: copper/zinc SOD
(CuZn-SOD, SOD1), which is located in the cytoplasm,2 Journal of Amino Acids
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in the cell. Mred or Mox, reduced or oxidized form of metals;
SOD, superoxide dismutase; GSH, reduced glutathione; GSSG,
oxidized glutathione; GR, glutathione reductase; GPx, glutathione
peroxidase; NADPH or NADP+, reduced or oxidized nicotinamide
adenine dinucleotide phosphate; VC, vitamin C; VE, vitamin E.
manganese SOD (Mn-SOD, SOD2), which exists in the
mitochondrial matrix, and extracellular SOD (EC-SOD,
SOD3), which is also a complex of CuZn. Some CuZn-SOD
is also seen in the intermembrane space of mitochondria [6].
Van Remmen is one of the most inﬂuential leaders in
ageing research. She and her colleagues have reported several
ageing symptoms of hepatic carcinoma [7] and muscle
atrophy [8] in CuZn-SOD knockout mice. They also studied
the physiological role of several antioxidant enzymes in
longevity using gene-disrupting mice [9]. Notably, CuZn-
SOD-deﬁcient mice showed the multiple pathologies in
several tissues with decreased lifespan compared to wild-
type mice. Fujii and colleagues also indicated that hemolytic
anemia was triggered by autoantibody production in CuZn-
SOD-deﬁcient mice [10].
Our group has reported that CuZn-SOD-deﬁcient mice
showed skin thinning [11]a sw e l la si n c r e a s e dd r u s e n
formation, which is a typical characteristic of age-related
macular degeneration as neurodegeneration [12] and fatty
liver [13]. Taken together, these observations demonstrate
that CuZn-SOD knockout mice have the potential to be a
valuable animal model for investigating human ageing. On
the other hand, Shimizu and colleagues generated various
tissue-speciﬁc Mn-SOD conditional knockout mice using
a Cre-loxp system because total knockout of Mn-SOD
induces neonatal lethality in mice [14, 15], liver-speciﬁc Mn-
SOD knockout mice which show no obvious morphological
abnormalities or biochemical changes in the liver [16],
heart/muscle-speciﬁc Mn-SOD-deﬁcient mice which exhibit
dilated cardiomyopathy with the downregulation of speciﬁc
biomolecules in the mitochondria [17], and skeletal muscle-
speciﬁc Mn-SOD knockout mice which develop severe
disturbance of exercise activity without muscle atrophy
[18]. Furthermore, they found severe phenotypes in the
brains of brain-speciﬁc Mn-SOD-deﬁcient mice showing a
spongiform encephalopathy-like pathology associated with
gliosis[19]. The most abundant ROS within cells inﬂuencing
synaptic plasticity, memory function, and neuronal death is
considered to be the superoxide radical [20]; this suggests
that SOD plays a protective role in neurodegeneration.
We introduce the relevance of oxidative stress to AD in the
following section.
2. Aβ Theory inAlzheimer’s Disease
AD is generally characterized by the aggregation of amyloid
β (Aβ) in senile plaques. Aβ mainly consists of 40- and
42-residue amyloid β peptides (Aβ40, Aβ42), secreted from
amyloid precursor protein (APP) by two proteases (β-a n d
γ-secretases) [21, 22]. Aβ42 plays a more critical role in
the pathogenesis of AD than Aβ40 because Aβ42 aggregates
more extensively to form ﬁbrils and shows stronger neuro-
toxicity [23]. On the other hand, there is increasing evidence
that the oligomeric assembly of Aβ could induce memory
declineandsynaptotoxicityinAD[24],whilematureplaques
were reported to be nontoxic [25, 26] and to serve as a store
of the toxic assembly of Aβ [27].
Studies on several kinds of Aβ oligomer associated with
neurotoxicity or synaptotoxicity have been accumulated.
Recently,Teplowandcolleaguessummarizedandoverviewed
Aβ assembly [28]: paranucleus, protoﬁbrils (24–700mer)
[29], Aβ-derived diﬀusible ligands (ADDL, ∼53kDa) [30],
Aβ∗56 (∼56kDa, 12-mer) [31], amylospheroid (∼150–
700kDa) [32], AβO( ∼90kDa, 15–20mer), annulus (150–
250kDa), and βamyball. Selkoe and colleagues suggested
that Aβ dimers are the smallest synaptotoxic species and
that plaque cores are largely inactive but sequester or release
dimers [33]. They developed unique oligomer speciﬁc-
ELISA using 82E1 antibody, whose epitope is N-terminal,
for both antigen capture and detection, to reveal a clear
correlation of the oligomer levels in the plasma and brain
extracts with various cognitive levels of AD patients [34].
Oligomeric molecules of Aβ are believed to consist of 2 or
3x n-multimers based on the dimer or trimer, respectively.
To elucidate the mechanism of Aβ oligomerization, many
scientists have developed a method or detection tools. Bitan
and colleagues created a method of the photoinduced cross-
linking of unmodiﬁed proteins to prepare the oligomers
in large quantity [35]. Glabe and colleagues generated a
conformation-dependent antibody (A11 clone) against Aβ
oligomers, which does not recognize ﬁbrils and also reacts
withothertypesofamyloidoligomers,suchasα-synucleinin
Parkinson’s disease, polyglutamine in Huntington’s disease,
and prion peptide 106–126 in prion disease [36]. Recently,
they reported the ﬁbril-speciﬁc, conformation-dependent
antibody (OC clone), recognizing soluble oligomers ranging
from a dimer to greater than 250kDa [37].
3. Role of Trace Metals andFormation of
Aβ RadicalinAlzheimer’s Disease
In 1965, Terry and Pena. ﬁrst reported the relevance of
aluminum to the pathology of AD; they injected aluminum
salts into the rabbit brain, resulting in neuroﬁbrillary tangle
formation [38], which is another hallmark of AD. Although
aluminum in the diet or drinking water had been long
believed as a risk factor for AD [39], Ehmann et al. in 1986
showed that this hypothesis for AD was an artifact [40].Journal of Amino Acids 3
It is known that transition metals, such as Cu, Zn, and
Fe, are enriched in senile plaques [41]. Aβ causes protein
oxidation, DNA/RNA oxidation, and lipid peroxidation in
vitro and in vivo, possibly by aggregating to generate radicals
viaatraceofmetalions(CuandZn)[41–44].Theimbalance
of copper homeostasis is also implicated in the etiology
of AD [45]. The neurotoxic eﬀects of Aβ42 and Aβ40 in
cell culture correlate with the ability to reduce Cu(II) to
Cu(I) and to generate H2O2 in a cell-free system [46].
The direct interaction of metals with Aβ in the N-terminal
region is essential for its aggregation and neurotoxicity. In
complex formation with Cu(II) [47, 48], each of the three
histidine residues at positions 6, 13, and 14 of Aβ42, Tyr10
[46, 49–52], and Asp1/Asp7 [53] may be involved. Recent
ESR studies by Drew et al. suggested that the Ala2 carbonyl
could be involved in the Cu(II) coordination [54]. Tyr10
is easily oxidized to the tyrosyl radical by Cu(II), leading
to the production of H2O2 [55]. Quite recently, Ono et
al. reported that UK (H6R) and Tottori (D7N) mutations
in the N-terminal regions accelerated the ability to form
oligomers and enhanced cytotoxicity [56]. These mutations
might change the binding mode of metal with Aβ peptides,
resulting in the increased ability to form toxic oligomers.
Based on the metal etiology in AD, therapeutics using
metal chelators might be promising to prevent plaque
formation by extracting the metals. Bush and colleagues
treated an APP transgenic mouse with a CuZn chela-
tor, clioquinol (8-hydroxy quinoline), showing the eﬀective
removal of plaque depositions [57]; however, it might alter
the homeostasis of copper and counteract the intracellular
copper-depleting eﬀects of APP in initial clinical trials of the
treatment of AD [58]. Eventually, it was removed from the
market by FDA due to diﬃculties associated with chelation
of Co(II) involved in vitamin B12. They also mentioned
that the problems were also due to the large magnitude
diﬀerence in aﬃnity of Cu(II) between clioquinol and Aβ42,
inwhichKd ofCu(II)forclioquinolandAβ42arenanomolar
and attomolar, respectively [59]. Other processes for plaque
removal by clioquinol could be involved. Recently, they
advanced the chelating strategy into the second-generation
clioquinol analogue, PBT2, which outperformed clioquinol
by markedly decreasing soluble interstitial Aβ and rescuing
cognitive impairment [60]. PBT2 was already found to
reverse frontal lobe functional deﬁcits and to decrease Aβ42
in a phase IIa clinical trial [61].
Butterﬁeld and colleagues pioneered the contribution
of Met35 to the neurotoxicity and oxidative eﬀects of Aβ
[44, 62]. The oxidized form of Met35 was detected both
in the brains of AD patients [63] and the APP transgenic
mouse model [64]. They suggested the reactive form of
Met35 in Aβ42 as an S-oxidized radical cation, abstracting
an allylic hydrogen of phospholipid acyl chains to give allyl
radicals,followedbylipidperoxidation[43].Themethionine
sulfoxide reductase is known to reverse methionine oxida-
tion. Moskovitz and colleagues reported that a knockout
mouse of one isoform of this enzyme caused enhanced
neurodegeneration in the brain hippocampus, implying that
the oxidation of Met residue plays a role in brain pathology
[65]. The S-oxidized radical cation in Met35 is generally
too unstable to cause oxidative damage continuously [66].
A stabilization mechanism for long-lasting oxidative stress in
AD progression is required. We have proposed the emerging
role of the turn formation at Glu22 and Asp23 in the
pathogenesis of AD [67, 68] and its contribution to oligomer
formation [69] following intracellular amyloidgenesis [70].
Our continuous studies using a systematic proline replace-
ment, solid-state NMR, and ESR have elucidated Aβ42-
mediated neurotoxicity in vitro; the central turn formation
could bring Tyr10 radical generated through trace metals
accompanied by the generation of H2O2,w h i c ha r em o v e d
close to Met35, resulting in the production of the S-
oxidized radical cation (Figure 2(a)). The systematic proline
replacement of Aβ42 proposed that not only the turn
formation at Glu22 and Asp23 but the turn at Gly38 and
Val39 increases aggregation and neurotoxicity [71]. This
additional C-terminal turn could enable the carboxylate
anion at Ala42 to interact with the S-oxidized radical cation
by forming S-O bonding through an intramolecular β-sheet
at positions 35–37 and 40–42 (Figure 2(a)). The resultant
hydrophobic core in the C-terminus would enhance Aβ42
aggregation, sequestering or releasing the radical species for
long-lasting oxidative stress in AD. If considered for the
lower toxicity of Aβ40 toxicity, the S-oxidized radical cation
of Met35 might not be fully stabilized by the incomplete
association of Met35 radical with the carboxylate anion at
Val40 (Figure 2(a)) or by the labile electrostatic interaction
between the sulfur atom of Met35 and the amide carbonyl
group of Ile31 under the condition of α-helix formation
in the C-terminal region [72]. Collectively, the formation
of toxic Aβ radicals generated through trace metals could
induce the malfunction of signal transduction pathways
after the interaction with membranes. This mechanism
(Figure 2(a)) can in part explain why Aβ42 is more neuro-
toxicthanAβ40[73].Thefollowinggenerationofsuperoxide
radical and hydroxyl radical occasionally accompanied with
the stabilization of Aβ42 radical could attack the membranes
and other macromolecules (Figure 2(b)). At least two Aβ42-
mediated pathways are assumed.
Recently, Butterﬁeld and colleagues advanced the Met35
theory into in vivo analysis using APP transgenic mice with
V717F (Indiana) and M631L mutations corresponding to
the substitution of Met35 with Leu in the Aβ sequence [74],
which showed the prevention of oxidative damages in tissues
andsenileplaqueinthebrain.Unexpectedly,M35Lmutation
in mice exhibited almost no eﬀects on memory and learning
impairments in the Morris water maze [74], indicating that
oxidative stress may be neither required nor suﬃcient for
memory loss. Quite recently, Bitan and colleagues suggested
that Met35 is not necessary for Aβ toxicity despite its
signiﬁcant role in aggregation [75]. Other mechanisms in
addition to Met35 will occur for the complete explanation
of Aβ42-induced neurotoxicity.
A relationship between Aβ oligomers and oxidative stress
has been noted; Klein and colleagues proposed that ADDL
induce long-term potentiation associated with oxidative
damage in vitro [76]. Barnham and colleagues proposed
that Aβ generated dityrosine cross-linked dimers through
oxidation of the phenolic hydroxyl group at Tyr10 under4 Journal of Amino Acids
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Figure 2: (a) Proposed mechanism of formation and stabilization of Aβ42 radical for long-lasting oxidative stress in AD and the toxic
conformer of Aβ42 [73]. (b) Scheme of generation of Aβ42-mediated radical species (superoxide radical and hydroxyl radical) and the
long-lasting Aβ42 radical in the pathogenesis of AD.
oxidative conditions [55], and that generic dityrosine levels
were increased in the AD brain [77]; however, it is unclear
whether Aβ-mediated oxidative damage observed in vitro is
relevant to in vivo disease.
4. OxidativeStressand Antioxidantsin
Alzheimer’sDisease
There is increasing evidence that oxidative stress is a
prominent and early feature of AD [78]. The Fenton reaction
mediated by iron or copper can result in the oxidative
damage of nucleic acids. Smith and colleagues proposed that
8-OHdG is an established marker of nuclear DNA oxidation
for AD pathology [78]. Butterﬁeld and colleagues proposed
that HNE is produced by Aβ-induced lipid peroxidation
[79]. Redox proteomics using human AD brains showed that
the elevation of TBARS was associated with the numbers of
neuritic but not diﬀuse plaques [80].
On the other hand, glutathione (GSH), a tripeptide,
is biosynthesized in the cytoplasm and normally exists in
the mitochondrial matrix as a reduced form [81]b e c a u s e
glutathione reductase (GR) plays a role in maintaining the
ratio of GSH toGSSG through the oxidation of nicotinamide
adenine dinucleotide phosphate (NADPH) (Figure 1). GSH
maintains the integrity of the plasma membrane and
adenosine triphosphate (ATP) in the synaptosomes as an
antioxidant. Under severe oxidative stress, the accumulation
of GSSG occurs together with protein modiﬁcation. Studies
using AD brains by Balaz and Leon revealed almost no
changes in the levels of glutathione and catalase [82], which
is an important enzyme to convert H2O2 into H2Oa n dO 2
(Figure 1). In contrast, Gsell et al. reported the decreased
activity of catalase in AD brains [83]. Some markers of
oxidative stress will be vulnerable or not to the formation
of Aβ radical in AD pathology. Alternatively, the technical
artifact during the isolation of proteins may aﬀect the results
for oxidative levels among diﬀerent research groups.
Table 1 summarizes in vivo studies on the involvement
of these enzymes in AD. The cytochrome c oxidase (COX)
is involved in respiratory electron transport in the mito-
chondrial inner membrane. There are several studies on the
correlation of the reduced activity of COX and increased
oxidative stress in AD brains [93, 94]. Fukui et al. crossed
an AD transgenic mouse with a neuron-speciﬁc COX10
knockout mouse and reported that COX deﬁciency failed
to increase both senile plaques and oxidative damage in AD
progression in contrast to their expectations [90]. NADPH
oxidase, believed to be one of the major ROS sources in the
brain, participates in the generation of superoxide radical by
transferring electrons across the membrane into molecular
oxygen [95]. Genetic inactivation of Nox2, an isozyme of
the catalytic subunit of NADPH oxidase, prevented oxidativeJournal of Amino Acids 5
Table 1: Studies on involvement of oxidative stress in AD in vivo.
Objected mice APP mice Behavior Aβ-dependent
pathology ROS marker References
CuZn-SOD KO Tg2576 Early memory loss Oligomer↑,P - t a u ↑ 8-OHdG↑,P r o t e i n
carbonyls↑
Submitted
CuZn-SOD Tga Tg1130H NT Cerebral dysfunction↓ NT [84]a
Mn-SOD hetero KO Tg2576b,J 2 0 c,
Tg19959d Early memory lossc Aβ depositions↑c,d,
P-tau↑b, NT [85]b,[ 86]c,[ 87]d
Mn-SOD Tg Tg2576e, Tg19959f Improved memory
losse,f
Aβ42/ Aβ40↓e,
Plaque↓f,
DHE↓e, Catalase↑f,
Protein carbonyls↓f,
[88]e,[ 89]f
COX10 KO APPswe/PSEN1ΔE9 NT Plaque↓,A β42↓ 8-OHdG↓,P r o t e i n
carbonyls↓
[90]
Nox2 KO Tg2576 Improved
abnormal behavior
Unchanged (Aβ42,
Aβ42, plaque) DHE↓ [91]
α-tocophenol transfer
protein KO Tg2576 NT Aβ40↑,I D E ↓ Unchanged [92]
Abbreviations: Aβ,a m y l o i dβ; AD, Alzheimer’s disease; APP, amyloid precursor protein; COX, cytochrome c oxidase; DHE, dihydroethidium; IDE, insulin-
degrading enzyme; KO, knock out; Nox, NADPH oxidase; NT, not tested; 8-OHdG, 8-hydroxydeoxyguanosine; PSEN, presenilin; P-tau, phosphorylated tau;
ROS, reactive oxygen species; SOD, superoxide dismutase; Tg, transgenic; ↑, increased; ↓, decreased.
stress,Aβ-derivedneurovasculardysfunction,andbehavioral
impairment without aﬀecting Aβ assembly [91]. Binding of
the transcription factor nuclear factor E2-related factor 2
(Nrf2) to the antioxidant response element (ARE) enhancer
sequence is known to induce the endogenous defense system
against oxidative stress. The Nrf2-ARE pathway is activated
in response to ROS, triggering the expression of antioxidant
enzymes. Kanninen et al. reported that intrahippocampal
injection of Nrf2 mitigated the spatial impairment of AD
mice (APP/PS1 mice) associated with increased plaque
formation and heme oxygenase-1 levels [96].
Glutathione peroxidase (GPx) is also a key modulator
in the neuronal system, participating in the elimination of
H2O2. Overexpression of GPx4, an isoform expressed in
the membrane, reduced the lipid peroxidation of mice after
exposure to diquat, known as a herbicide, and induced
mice resistant to apoptosis from oxidants [97]. Embryonic
ﬁbroblasts of catalase transgenic mice are more resistant to
toxic H2O2 [98]. Thioredoxin plays a role in repairing the
oxidation of cysteine residues in proteins [99]. Yodoi and
colleagues generated transgenic mice overexpressing human
thioredoxin, which reduced oxidative stress and extended its
lifespan [100]. The therapeutic eﬀects of these antioxidative
enzymes against AD are expected although no studies on
their role in AD pathology have been reported.
5. Therapeutic Role of SuperoxideDismutase in
Alzheimer’sDisease
The role of SOD in AD pathogenesis has long been
controversial. Several studies have shown decreased SOD
in the frontal cortex of AD patients [101] whereas a slight
elevation of SOD was documented in the caudate nucleus
of AD patients [102]. Alternatively, other researchers have
suggested that almost no changes in SOD levels are found in
AD brains [83]. Quite recently, Ansari and Scheﬀ reported
a strong correlation between several oxidative damage levels
using various dementia subjects with negligible levels of
premortem hypoxia in order to eliminate the possibility
of aﬀecting protein integrity [103]. As shown in Table 1,
Melov et al. suggested that mitochondrial oxidative stress
could induce the hyperphosphorylation of tau at Ser396
using Tg2576 transgenic AD mouse model [85]. There
have also been reports on the role of Mn-SOD in AD
pathology; AD transgenic mouse models crossed with
Sod2+/− resulted in increased accelerated behavioral deﬁcits
[86] or senile plaques [87]( Table 1). Quite recently, our
group proposed the involvement of CuZn-SOD in AD
progression; the superoxide radical in the cytoplasma
induced Aβ oligomerization and early cognitive impairment
in Tg2576, and these phenomena notably preceded oxidative
damage (Murakami, K. et al., submitted) (Table 1). Our
ﬁndings do not contradict the implication by Marlatt et al.
that oxidative damage occurs primarily within the cytoplasm
rather than the mitochondria [3].
In the therapy of AD by SODs, cerebral endothelial
dysfunction in the AD mouse model can be improved by
overexpression of Sod1 [84]( Table 1) or the administration
of SOD [104]. Bayer et al. proposed that dietary intake of Cu
stabilizes CuZn-SOD activity and decreases Aβ production
in the APP transgenic mouse model [105]. On the other
hand, overexpression of Sod2 rescued several markers for
oxidative stress associated with AD-like pathologies in two
representative lines of AD model mice (Tg2576 [88]a n d
Tg19959 [89]) (Table 1). Under the excessive reduced redox-
acitve metal ions, the adverse eﬀe c t sd u et oh y d r o x y lr a d i c a l
formation should be taken into account. The therapeutic
treatment of both SOD and catalase mimetics (e.g., EUK-8
[106]) could be one of promising approaches.
Breteler and colleagues performed a clinical survey of
the dietary intake of antioxidants and the risk of AD based
on over 5,000 participants in the Netherlands [107]. It
was suggested that high dietary intake of vitamin C and
vitamin E might lower the risk of AD. Dementia control by6 Journal of Amino Acids
vitamin C and vitamin E has long been discussed [108–112].
Interestingly, Rinaldi et al. suggested the correlation of
vitamin C and SOD levels with the dementia status [113].
SOD might be one of the most vulnerable indicators as
an antioxidant enzyme in AD and cognitive dementia.
Alternatively, it was reported that environmental enrichment
prevented AD-like pathology associated with elevated CuZn-
SOD and Mn-SOD levels [114].
6. Conclusions
One of the most accepted knowledge in the etiology of AD
is thought to be the free-radical theory; however, it remains
to be determined whether oxidative stress is a cause or eﬀect
in AD. Aβ42 aggregates (oligomerizes) induce neurotoxins
by interacting with trace metals at Tyr10 or in the N-
terminal region, leading to tissue oxidation by an S-oxidized
radical cation in Met35. There are three means of defense
from Aβ42-dependent AD pathology: (1) to slow the rate
of Aβ42 aggregation, (2) to decrease the production of
Aβ42 by downregulating the activity of β-o rγ-secretase,
and (3) to enhance protease activity (such as neprilysin
[115], an insulin-degrading enzyme [116]) against Aβ42.
Oxidative stress may aﬀect one or all of the protective
mechanisms. Antioxidant enzymes including SOD or dietary
supplements of vitamin C and vitamin E could counteract
these dysfunctions. Food treatments for prevention are
a better choice to maintain the quality of life. There
are increasing reports on the inhibitory eﬀects of natural
products such as several ﬂavonoids [117], vitamin A [118],
and vitamin E [119] on AD pathology in vivo. Nishida et al.
reported α-tocophenol transfer protein-knockout mice, in
which Aβ deposits accumulated by decreasing the clearance
of Aβ peptide from the brain and blood [92]( Table 1).
Quite recently, we discovered the potential of silymarin
[120], the active ingredient of milk thistle extract which is
long used as a hepatoprotective medicine, and vitamin C
(Murakami, K. et al., submitted) for AD prevention. Further
research on structural analysis of the inhibitory mechanism
is under investigation to eﬀectively develop inhibitors with
few adverse eﬀects.
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